Sight Sciences, Inc.
Our mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases.
Our currently marketed products, the OMNI Surgical System, or OMNI, and the TearCare System, or TearCare, target two of the world’s most prevalent and underserved eye diseases, glaucoma and dry eye disease, or DED, respectively. Glaucoma, a group of chronic, often asymptomatic, diseases that damage the optic nerve, is the world’s leading cause of irreversible blindness. Primary open-angle glaucoma, or POAG, is the most prevalent form of glaucoma. Dry eye complaints are the most common reason for a patient visit to an eye doctor and DED symptoms have a significant impact on the quality of life and productivity of patients. If left untreated, DED can be extremely painful, leading to permanent cornea damage and vision impairment. We estimate the annual addressable U.S. market opportunities for OMNI and TearCare are approximately $6 billion and approximately $10 billion, respectively, while 2020 U.S. manufacturer revenues in the surgical glaucoma and DED markets were approximately $350 million and $2.4 billion, respectively, demonstrating that currently available solutions have not addressed a large part of the market need.
OMNI is a handheld, single-use, therapeutic device that allows ophthalmic surgeons to reduce intraocular pressure, or IOP, in adult glaucoma patients with a safe and minimally invasive glaucoma surgery, or MIGS. The FDA has authorized the use of OMNI for reducing IOP in all adult POAG patients both by itself on a standalone basis, which we refer to as Standalone procedures, or in combination with cataract procedures, which we refer to as Combination Cataract procedures.
TearCare is a technologically sophisticated system which utilizes a wearable, open-eye design to apply localized heat to eyelids in an anatomically customized way.
(Note: Sight Sciences priced its upsized IPO on July 14, 2021, in line with its recently revised terms: 10 million shares at $24 – the top of its new $23-to-$24 price range. Earlier in the day, Sight Sciences upsized its IPO by 56.5 percent to 10 million shares, up from 6.98 million shares, and raised the price range to $23 to $24 – up from its original price range of $20 to $23 – .07 million) – in an S-1/A filing dated July 14, 2021.)
|Industry:||SURGICAL & MEDICAL INSTRUMENTS & APPARATUS|
|Address||4040 Campbell Ave, Suite 100 Menlo Park CA 94025|
|View Prospectus:||Sight Sciences, Inc.|
|Revenues||$29.7 mil (last 12 months)|
|Net Income||$-37.7 mil (last 12 months)|
|Price range||$24.00 - $24.00|
|Est. $ Volume||$240.0 mil|
|Manager / Joint Managers||Morgan Stanley/ BofA Securities/ Citigroup/ Piper Sandler|
|Expected To Trade:||7/15/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|